Great — here’s a compact, sourced market reference for the Bipolar Disorder Market with company references and values where available, plus the sections you requested. I pulled the latest market reports, regulator/company news and clinical literature so the key points are dated and citable.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Bipolar Disorder market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Bipolar Disorder market.

Read complete report at: https://www.thebrainyinsights.com/report/bipolar-disorder-market-13033

Market snapshot (size & outlook)

• Reported market-size estimates vary by source and scope (drugs + devices + digital therapeutics vs. drugs only). Representative figures: USD 4.9B (2023) per Grand View Research; many market reports place the 2024–2025 market in the USD 4.3–5.7B range and forecast CAGRs of ~2.5–4% through the early 2030s (ranges reflect different definitions and horizons). 

Company references & notable values (selected)

• Johnson & Johnson / Janssen (Caplyta / lumateperone via Intra-Cellular acquisition) — J&J agreed to acquire Intra-Cellular Therapies (lumateperone/Caplyta) in a large neuroscience bet; Caplyta has shown rising sales (~USD 240M in a recent quarter) and recent label expansions. This is material to bipolar-depression segment dynamics.

• AbbVie & Gedeon Richter (Vraylar / cariprazine) — Vraylar is a major, high-growth bipolar franchise (reported AbbVie Vraylar-related revenue increases; one reported AbbVie figure cited ~USD 2.76B for Vraylar-related sales growth in recent reporting cycles). Vraylar covers manic, depressive and mixed bipolar I episodes and represents a large share of newer-entrant antipsychotic sales.

• AstraZeneca / Seroquel (quetiapine) — Seroquel (quetiapine) remains an established bipolar treatment historically; rights/marketing arrangements have shifted (AstraZeneca divested certain rights; generics are now widely used).

• Eli Lilly (Zyprexa / olanzapine), Sumitomo Dainippon / Sunovion (Latuda / lurasidone) — these legacy and second-generation antipsychotics remain important for bipolar-spectrum prescribing (Zyprexa, Latuda indicated for bipolar depression in certain uses).

Note: many bipolar products are older branded molecules now with large generic volumes; the market’s high-value growth drivers are newer branded entrants (e.g., Vraylar, Caplyta) and label expansions. Where exact HCP-level net product revenues are needed for each company, I can extract line-items from 2023–2024 investor reports for specific names you pick.

Recent developments

• Label expansions & new approvals (notably lumateperone/Caplyta indications for bipolar depression and MDD adjunctive use) and large M&A (J&J’s acquisition of Intra-Cellular) reshaping the competitive landscape.

• Patent cliffs & generic entry on older antipsychotics (affects pricing, margins, and market share).

Drivers

• Growing diagnosis & awareness of mood disorders and improved screening/diagnostics.

• Shift to novel branded agents with favorable tolerability or targeted indications (drives premium sales).

• Investment in neuroscience / M&A (large pharma acquiring specialty neuropsychiatry companies) fueling new commercial activity.

Restraints

• Modest market growth relative to other therapy areas (many effective generics keep overall spend growth low).

• Safety/tolerability concerns and metabolic side effects (limits some drugs’ long-term use and uptake).

• Reimbursement and access variability across regions, and stigma/underdiagnosis limiting treated population share.

Regional segmentation analysis

• North America: largest current revenue share (strong payer systems for specialty psychiatry, rapid uptake of new branded agents).

• Europe: mature market with conservative formulary access in some countries (mix of branded/generic).

• Asia-Pacific: fastest-growth potential (large patient base, rising mental-health awareness and premiumization in urban markets).

Emerging trends

• New branded antipsychotics and targeted mood-depression approvals (e.g., lumateperone expansion).

• Digital therapeutics & remote monitoring to support mood tracking, adherence and early intervention (an adjunct growth channel).

• Combination strategies (adjunctive use with mood stabilizers like lithium/valproate and personalized prescribing).

Top use cases (therapeutic / commercial)

1. Acute mania and maintenance therapy to prevent recurrence (mood stabilizers + antipsychotics).

2. Bipolar depression (an increasingly important commercial segment — drugs approved specifically for bipolar depression command premium pricing).

3. Adjunctive treatments for treatment-resistant mood symptoms.

Major challenges

• Demonstrating long-term benefits & safety (metabolic risk, movement disorders) needed for broader label expansion and payer reimbursement.

• Fragmentation of treatment paradigms (wide use of older generics vs. selective uptake of new agents).

Attractive opportunities

• Label expansion and new indications (e.g., Caplyta’s recent approvals create revenue upside).

• Digital/adjunct care models (monitoring, adherence, combined pharma + digital service bundles).

• Emerging-market penetration (APAC) as awareness and access improve.

Key factors of market expansion

• Successful commercialization of newer agents with demonstrable advantages in efficacy/tolerability (driving premium uptake).

• Improved diagnostics & reduced stigma increasing treated prevalence and continuity of care.

• Payer acceptance & guideline incorporation of newer agents for bipolar depression and maintenance.

If you want, I can now (pick one) and I’ll produce it immediately:

1. A competitor table (company / lead bipolar product(s) / latest annual revenue for that product or closest proxy / primary region).

2. Pull exact sales numbers and recent quarterly/annual HCP-level revenues for 3 named companies (e.g., J&J (Caplyta), AbbVie (Vraylar), Sumitomo/Lundbeck or AstraZeneca).

3. Build a 2-slide market brief PPT (market size + top players + opportunities + citations).

Which of the three should I generate next?